Business Wire

Fluence Lines Up 2300 Megawatt-hours of Orders for Sixth-Generation Energy Storage Technology From Customers Including Enel, LS Power, sPower and Siemens

16.6.2020 14:00:00 EEST | Business Wire | Press release

Share

Fluence, a Siemens and AES company, today unveiled its sixth-generation energy storage technology stack combining factory-built hardware, advanced software and data-driven intelligence. Drawing on more than 12 years of industry leadership and innovation, the new technology is changing the way energy storage systems are built and operated — making them simpler, safer, faster and more cost-effective to deploy at scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005326/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence's three purpose-built energy storage systems (Photo: Fluence)

The technology stack creates the foundation for three purpose-built systems, GridstackTM, SunstackTM and EdgestackTM, that are configured for grid, renewable and commercial & industrial (C&I) applications, respectively, while easily addressing the need for larger systems and larger fleets of systems. Fluence has already been selected by leading customers such as Enel, LS Power, sPower and Siemens for 800 megawatts, 2300 megawatt-hours, of projects using the new technology.

“Energy storage applications require highly flexible systems that can be tailored to specific markets and customer needs,” said Fluence CTO Brett Galura. “Until now, customers were forced to choose between custom-built solutions or inflexible, vertically integrated products. This sixth-generation technology combines our proprietary dataset – among the industry’s largest – and our deep industry experience to deliver unparalleled intelligence and flexibility, while adding the benefits of mass production to standardize safety features and significantly reduce the time and cost needed to deploy energy storage. Over the past decade, Fluence has reduced the total cost of energy storage systems by 90 percent; our new technology stack focuses on driving down the non-battery costs of energy storage systems by up to 25 percent, while empowering gigawatt-sized deployments.”

Fluence’s new technology stack includes three components:

  • Fluence IQ: Digital intelligence engines use data and machine learning to improve system decision-making, manage battery degradation, reduce operating costs and optimize energy market dispatch.
  • Fluence Operating System (OS): Built on a decade of digital control system development, the fully integrated operating platform combines comprehensive controls, system visibility and asset management to improve asset performance at a single site or across entire fleets.
  • Fluence Cube: The factory-assembled building block is 4-5x more modular than traditional systems and incorporates the latest technologies for rapid installation and scale, consistent operations & maintenance and improved quality control.

Fluence Cube, OS and IQ incorporate enhanced safety features to meet the most stringent safety standards, such as NFPA 855 and UL 9540A. Together, they provide the foundation for three pre-configured energy storage systems optimized for specific market segments and project needs:

  • Gridstack: A utility-scale system designed for the most demanding grid applications (such as T&D enhancement, frequency regulation and capacity peak power), with industry-leading reliability and safety.
  • Sunstack: A PV-optimized, co-located system designed to improve and expand the capabilities of solar generation with firm renewable energy delivery and additional grid services.
  • Edgestack: A commercial & industrial system designed to support 500+ kW applications with rapid deployment and minimum footprint to reduce demand charges and provide critical power.

Major global power suppliers and industrial customers have already committed to deploy Fluence’s sixth-generation technology in Asia Pacific, North America and Europe. Siemens is delivering Gridstack and Edgestack for customers in Germany, Portugal and Finland.

“Battery storage is a rapidly growing segment and crucial for the energy transition. For the cost-efficient and fast execution of projects in the area of distributed energy, microgrids and eMobility infrastructure, the productization and modularization of storage technologies are decisive. With the new stack & OS approach, Fluence has a unique system providing cutting-edge safety,” said Jean-Christoph Heyne, Global Head of Future Grids, Siemens AG.

“Cost-competitive technologies, aggressive emissions targets and increased need for grid reliability and resilience are driving global utility and C&I demand for energy storage, which BloombergNEF predicts will attract more than $560 billion in investment by 2040,” said Fluence CEO Manuel Perez Dubuc. “What separates our carbon-intensive past from a sustainable future is market inflection. With the introduction of our next-generation design, Fluence is helping drive that inflection, making it more cost-effective, faster and safer to replace smokestacks with tech stacks that provide communities around the world with cleaner, more resilient energy systems.”

About Fluence

Fluence, a Siemens and AES company, is the global market leader in energy storage technology solutions and services, combining the agility of a technology company with the expertise, vision and financial backing of two well-established and respected industry giants. Building on the pioneering work of AES Energy Storage and Siemens energy storage, the company’s goal is to create a more sustainable future by transforming the way we power our world. Providing design, delivery and integration, Fluence offers proven energy storage technology solutions that address the diverse needs and challenges of customers in a rapidly transforming energy landscape. The company currently has more than 2.1 gigawatts of projects in operation or awarded across 22 countries and territories worldwide. Fluence topped the Navigant Research utility-scale energy storage leaderboard in 2018 and was named one of Fast Company’s Most Innovative Companies in 2019.

To learn more about Fluence, please visit: fluenceenergy.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alison Mickey, director of communications
E: alison.mickey@fluenceenergy.com
O: 703-721-8818

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye